Navigation Links
Researchers explore new driver of transplant rejection: Platelets
Date:2/17/2009

cells, Morrell says, recruiting them from far and wide to stave off potential infections.

These are on the whole very good things for platelets to do, Morrell says, but in the context of organ transplants, their pro-inflammatory function gets out of control, and they do more bad than good after contributing to initial wound healing.

Strategies using drugs or other means to keep platelets quiet and non-inflammatory might benefit transplant patients in the long run because chronic rejection as contrasted with acute or immediate organ rejection is a major complication for which there is little current treatment, according to Hamid Rabb, M.D., medical director of kidney transplantation and a professor of medicine at the Johns Hopkins University School of Medicine.

In prior research using mice with skin transplants, Morrell and his team noted that increased platelet interactions led to increased and prolonged white cell interactions with the inner lining of the blood vessels and worsened transplant vessel damage.

"We watched platelets flowing through the blood vessels of transplanted skin in mice with and without platelets and determined tissue-platelet interactions by comparing the speeds of those flows," says Morrell, whose team ultimately demonstrated that antibodies made in reaction to the transplanted tissue sparked platelet activation and white cell recruitment.

Studies on tissue from platelet-depleted mice helped confirm the importance of platelets in white cell activation and recruitment, strongly suggesting that limiting the inflammatory response might improve transplanted tissue survival.

Mounting evidence suggesting that platelets are activated not only post-transplant, but also during organ harvest, presents new opportunities for attacking organ injury and rejection head-on, says Rabb. The traditional target of current anti-rejection medicine is the so-called T lymphocyte a white blood cell believed to
'/>"/>

Contact: Maryalice Yakutchik
myakutc1@jhmi.edu
443-287-2251
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Forget the antioxidants? McGill researchers cast doubt on role of free radicals in aging
2. Researchers isolate protein domain linked to tumor progression
3. CSHL researchers identify gene that helps plant cells keep communication channels open
4. Researchers identify gene linked to aggressive progression of liver cancer
5. Case Western Reserve researchers looking at light-induced toxins in air and water
6. McMaster researchers discover new mode of how diseases evolve
7. Researchers shed new light on connection between brain and loneliness
8. Texas researchers provide emissions data for livestock industry
9. Biodiversity itself begets a species cascade, researchers say
10. NYU Langone Medical Center researchers find micro RNA plays a key role in melanoma metastasis
11. While focusing on heart disease, researchers discover new tactic against fatal muscular dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2015)... GOTHENBURG, Sweden , June 16, 2015 ... 2015 from previously communicated that it will amount to at ... 390 MSEK. Due to the rapid increase in market growth ... from the previously communicated guidance that revenue for 2015 will ... 2015 will amount to approximately 2,200 MSEK. Due ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... patent to electronically capture, analyze and identify participants ... recognition methods. This system can: ... an enrollment and subsequent sign-on process is actually ...
(Date:6/9/2015)... -- Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ) has ... & Touchless Sensing Market by Technology (Touch-based & ... (Biometric & Sanitary Equipment) & by Geography - ... offering. The total gesture recognition and ... 23.55 Billion by 2020 at a high CAGR ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... bugs grow in intensive care units to develop a ... MRSA and other superbugs in the environment, scientists heard ... General Microbiologys 162nd meeting being held this week at ... a standard sampling regime to take swabs from sinks, ...
... deadliest diseases, caused by the Ebola virus, may finally ... have successfully tested several Ebola vaccines in primates and ... Dr Anthony Sanchez, from the Centers for Disease ... overview of Ebola vaccine development today (Monday 31 March ...
... Multi-Modal Biometric Identification Solution ... and Interoperability, SCHAUMBURG, Ill., March 28 ... it has been selected by the West Virginia,State ... (BIS). Motorola,s latest BIS solution features new algorithms ...
Cached Biology News:MRSA in hospital intensive care -- what's growing where? 2Vaccine for Ebola virus 2Motorola Biometric Identification System Selected by West Virginia State Police 2
(Date:6/29/2015)...  AACC, a global scientific and medical professional ... is pleased to announce that the impact factor ... increased to 7.9 in the 2014 Thomson Reuters ... Chemistry in the top 3% of all ... the research it publishes on laboratory medicine and ...
(Date:6/29/2015)... 2015 According to a new market ... Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other Technologies), by ... - Global Forecast to 2020", published by MarketsandMarkets, the global ... from $107.56 Million in 2015, at a CAGR of 17.89%. ... 67 F igures spread through 125 ...
(Date:6/29/2015)... 2015   For the seventh year running, Across Health ... overall digital maturity called the Multichannel Maturometer . ... not maturing fast enough. While it,s true that technology ... overall and customers are increasingly "digital natives", pharma still ... engagement.  ...
(Date:6/26/2015)... CITY, Kan. , June 26, 2015 ... PETX ), a pet therapeutics company ... of innovative biopharmaceutical products for companion animals, ... field effectiveness study of capromorelin (AT-002), the ... dogs.  Capromorelin is a small molecule that ...
Breaking Biology Technology:AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5
... , Data Reported at the 2010 ASCO ... Both Time to Tumor Progression and Overall Survival in ... Arm , QUÉBEC CITY, Jan. 25 /PRNewswire-FirstCall/ ... AEZ) (the "Company"), a late-stage drug development company specialized ...
... thin films for semiconductors in electronic devices, layers of atoms ... materials grow smooth crystals, others tend to develop bumps and ... In the online edition of the journal Science ... how atoms arrange themselves into thin films. Led by assistant ...
... As ... bright spot in terms of employment growth. But that was offset by a rough ride for ... pharmaceutical companies going into 2010 are any indication, the trouble isn,t over just yet. , ... (Vocus) January 21, 2010 -- As one of ...
Cached Biology Technology:Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 2Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 3Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 4Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 5Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 6Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 7Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 8Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 9Watching crystals grow provides clues to making smoother, defect-free thin films 2The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs 2The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs 3The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs 4
...
Rabbit polyclonal to SMARCA2 / BRM - ChIP Grade ( Abpromise for all tested applications). entrezGeneID: 6595 SwissProtID: P51531...
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... skirted micro test tubes are used to ... these tubes have uniform walls for uniform ... separate O-ring screw caps. The O-rings are ... an operating range from -55 to 150 ...
Biology Products: